Abiomed Announces Second Quarter Fiscal 2014 Revenue of $44.3 Million, Up 19% Over Prior Year, Driven by Record Impella Utili...
November 06 2013 - 7:00AM
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough
heart support technologies, today reported second quarter fiscal
2014 revenue of $44.3 million, up 19% compared to revenue of $37.4
million in the same period of fiscal 2013, and a second quarter
fiscal 2014 GAAP net income of $1.1 million or $0.03 per diluted
share, compared to $5.5 million or $0.13 per diluted share in the
prior year period.
Financial and operating highlights during the second quarter of
fiscal 2014 and fiscal year to date include:
- Fiscal second quarter worldwide Impella® revenue totaled $40.2
million, up 23% compared to revenue of $32.8 million during the
same period of the prior year. U.S. Impella revenue grew 21% to
$37.0 million from $30.7 million in the prior year with U.S.
Impella patient usage up 24% from the prior year.
- An additional 30 hospitals purchased Impella 2.5 during the
quarter, bringing the total to 805 customer sites. As part of
Abiomed's continued Impella CP™ launch, an additional 65 hospitals
purchased Impella CP, bringing the total number of Impella CP U.S.
sites to 237. Impella 2.5 and Impella CP unit inventory at
hospitals averaged 2.4 units, equal to the prior sequential
quarter.
- Gross margin rate for the second quarter of fiscal 2014 was
79.6% compared to 80.8% in the second quarter of fiscal
2013. There were 172 Impella AIC consoles placed during the
quarter compared to 114 in the same period of the prior year.
- Income from operations for the second quarter fiscal 2014 was
$1.4 million, compared to $5.9 million in the prior year period.
Operating expense in the second quarter of fiscal 2014 included
$1.9 million related to the Department of Justice subpoena and $0.7
million of medical device tax.
- Cash, cash equivalents, short and long-term marketable
securities totaled $96.9 million as of September 31, 2013. The
Company continues to have no debt and a U.S. federal net operating
loss carry-forward of approximately $190 million as of March 31,
2013.
- Abiomed today announced that the Impella RP RECOVER RIGHT study
has enrolled more than 50% of the required patients and as a
result, HDE approval is forecasted for February 2015.
- In October, there were over 25 Impella-related sessions at the
Transcatheter Cardiovascular Therapeutics (TCT) 2013 conference in
San Francisco.
- In August, Abiomed received approval from the U.S. Department
of Veterans Affairs to be included on its authorized Veteran's
Administration (VA) Federal Supply Schedule, providing the Impella
platform to VA medical facilities, Department of Defense (DOD)
hospitals and other federal agencies.
"Abiomed achieved many new quarterly records on Impella
utilization, including most overall patients, most prophylactic
patients and most emergent patients," said Michael R. Minogue,
Chairman, President and Chief Executive Officer of
Abiomed. "We are on track to transform into a PMA and PMDA
company while setting new records in patient utilization and
completing enrollment in our Impella RP study."
The Company is maintaining its fiscal year 2014 revenue guidance
in the range of $180 million to $185 million, with worldwide
Impella revenue forecasted to increase by approximately 20%, and
GAAP operating margin of approximately breakeven to 5%.
The Company will host a conference call to discuss the results
on Wednesday, November 6, 2013, at 8:00 a.m. ET. Michael R.
Minogue, Chairman, President and Chief Executive Officer; Robert L.
Bowen, Vice President and Chief Financial Officer; and Susan V.
Lisa, Senior Director, Investor Relations and Corporate
Development, will host the conference call.
To listen to the call live, please tune into the webcast via
http://investor.abiomed.com or dial (877) 638-9567; the
international number is (253) 237-1032. A replay of this conference
call will be available beginning at 11 a.m. ET November 6, 2013
through 11:59 p.m. ET on November 13, 2013. The replay phone number
is (855) 859-2056; the international number is (404) 537-3406. The
replay access code is 86905153.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading
provider of medical devices that provide circulatory
support. Our products are designed to enable the heart to rest
by improving blood flow and/or performing the pumping of the heart.
For additional information please visit: www.abiomed.com
FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including
statements regarding development of Abiomed's existing and new
products, the Company's progress toward commercial growth, and
future opportunities and expected regulatory approvals. The
Company's actual results may differ materially from those
anticipated in these forward-looking statements based upon a number
of factors, including uncertainties associated with development,
testing and related regulatory approvals, including the potential
for future losses, complex manufacturing, high quality
requirements, dependence on limited sources of supply, competition,
technological change, government regulation, litigation matters,
future capital needs and uncertainty of additional financing, and
other risks and challenges detailed in the Company's filings with
the Securities and Exchange Commission, including the most recently
filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
Readers are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this
release. The Company undertakes no obligation to publicly release
the results of any revisions to these forward-looking statements
that may be made to reflect events or circumstances that occur
after the date of this release or to reflect the occurrence of
unanticipated events.
Abiomed, Inc. and
Subsidiaries |
Consolidated Balance
Sheets |
(Unaudited) |
(in thousands, except
share data) |
|
|
|
|
|
|
|
September 30,
2013 |
March 31, 2013 |
|
(unaudited) |
|
ASSETS |
|
|
Current assets: |
|
|
Cash and cash equivalents |
$10,120 |
$9,451 |
Short-term marketable
securities |
60,950 |
67,256 |
Accounts receivable,
net |
21,119 |
22,946 |
Inventories |
15,636 |
14,930 |
Prepaid expenses and other
current assets |
2,789 |
2,022 |
Total current assets |
110,614 |
116,605 |
Long-term marketable securities |
25,811 |
11,406 |
Property and equipment, net |
6,444 |
6,549 |
Goodwill |
37,349 |
35,410 |
Other assets |
801 |
29 |
Total assets |
$181,019 |
$169,999 |
LIABILITIES AND STOCKHOLDERS'
EQUITY |
|
|
Current liabilities: |
|
|
Accounts payable |
$6,182 |
$7,696 |
Accrued expenses |
13,722 |
15,162 |
Deferred revenue |
4,142 |
4,198 |
Total current liabilities |
24,046 |
27,056 |
Long-term deferred tax liability |
6,007 |
5,554 |
Other long-term liabilities |
262 |
309 |
Total liabilities |
30,315 |
32,919 |
Commitments and contingencies (Note 9) |
|
|
Stockholders' equity: |
|
|
Class B Preferred Stock, $.01
par value |
-- |
-- |
Authorized - 1,000,000 shares;
Issued and outstanding - none |
|
|
Common stock, $.01 par
value |
406 |
397 |
Authorized - 100,000,000
shares; Issued - 40,659,164 shares at September 30, 2013 |
|
|
and 39,788,383 shares at March
31, 2013; |
|
|
Outstanding - 39,452,797 shares
at September 30, 2013 |
|
|
and 38,601,384 shares at March
31, 2013 |
|
|
Additional paid in capital |
427,183 |
414,810 |
Accumulated deficit |
(258,925) |
(258,261) |
Treasury stock at cost -
1,206,367 shares at September 30, 2013 |
|
|
and 1,186,999 shares at March
31, 2013 |
(16,554) |
(16,129) |
Accumulated other comprehensive
loss |
(1,406) |
(3,737) |
Total stockholders' equity |
150,704 |
137,080 |
Total liabilities and stockholders'
equity |
$181,019 |
$169,999 |
|
Abiomed, Inc. and
Subsidiaries |
Consolidated Statements
of Operations |
(Unaudited) |
(in thousands, except
share data) |
|
|
|
|
|
|
Three
Months Ended September 30, |
Six Months Ended
September 30, |
|
2013 |
2012 |
2013 |
2012 |
Revenue: |
|
|
|
|
Product revenue |
$44,288 |
$37,319 |
$86,897 |
$75,966 |
Funded research and
development |
57 |
98 |
118 |
234 |
|
44,345 |
37,417 |
87,015 |
76,200 |
Costs and expenses: |
|
|
|
|
Cost of product
revenue |
9,027 |
7,194 |
17,750 |
14,640 |
Research and
development |
7,721 |
5,854 |
15,008 |
12,566 |
Selling, general and
administrative |
26,199 |
18,437 |
54,166 |
39,390 |
Amortization of intangible
assets |
-- |
-- |
-- |
111 |
|
42,947 |
31,485 |
86,924 |
66,707 |
Income from operations |
1,398 |
5,932 |
91 |
9,493 |
Other income (expense): |
|
|
|
|
Investment income (expense),
net |
25 |
1 |
41 |
(1) |
Other income (expense),
net |
6 |
(9) |
(15) |
(13) |
|
31 |
(8) |
26 |
(14) |
Income before income tax provision |
1,429 |
5,924 |
117 |
9,479 |
Income tax provision |
370 |
455 |
781 |
891 |
Net income (loss) |
$1,059 |
$5,469 |
$(664) |
$8,588 |
|
|
|
|
|
Basic net income (loss) per share |
$0.03 |
$0.14 |
$(0.02) |
$0.22 |
Basic weighted average shares
outstanding |
39,260 |
39,431 |
38,971 |
39,288 |
|
|
|
|
|
Diluted net income (loss) per share |
$0.03 |
$0.13 |
$(0.02) |
$0.21 |
Diluted weighted average shares
outstanding |
41,337 |
41,722 |
38,971 |
41,645 |
CONTACT: For further information please contact:
Susie Lisa, CFA
Senior Director, Investor Relations and Corporate Development
978-646-1590
slisa@abiomed.com
Aimee Genzler
Corporate Communications Manager
978-646-1553
ir@abiomed.com
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Apr 2024 to May 2024
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From May 2023 to May 2024